SCHEMBL2368917

SCHEMBL2368917

Cc1ccc(-c2csc3ncnc(Cl)c23)cc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.77
SMN1; SMN2 Q16637 5/20 0.77
HTT P42858 5/20 0.77
KMT2A Q03164 2/20 0.77
LMNA P02545 6/20 0.73
ALDH1A1 P00352 5/20 0.73
NPSR1 Q6W5P4 2/20 0.72
MEN1 O00255 1/20 0.56
GAA P10253 3/20 0.54
HPGD P15428 1/20 0.54
CSNK2A2 P19784 2/20 0.53
CSNK2B P67870 2/20 0.53
CSNK2A1 P68400 2/20 0.53
FGFR1 P11362 2/20 0.53
TSHR P16473 1/20 0.53
KDM4E B2RXH2 1/20 0.52
PIP4K2C Q8TBX8 1/20 0.52
ATM Q13315 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2369317 0.87 MAPT (1.00) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL2369140 0.84 SMN1; SMN2 (1.00) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL1604911 0.84 SMN1; SMN2 (1.00) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL6666685 0.84 MAPT (0.56) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL3163635 0.84 SMN1; SMN2 (0.77) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL2368374 0.84 SMN1; SMN2 (0.77) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL2253337 0.84 MAPT (1.00) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL2369017 0.84 HTT (0.71) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL2368934 0.84 SMN1; SMN2 (0.67) MAPTSMN1; SMN2HTTKMT2ALMNA
SCHEMBL6661733 0.81 NPSR1 (0.57) MAPTSMN1; SMN2HTTKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
CN-1823071-A Thienopyrimidine derivatives as potassium channel inhibitors XENTION DISCOVERY LTD (GB) 2006-08-23 CN disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed
US-20040138238-A1 Substituted aminopyrimidine compounds as neurokinin antagonists PREDIX PHARMACEUTICALS HOLDINGS, INC. 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 MAPT 2978/4885SMN1; SMN2 1520/4885HTT 543/4885
US-20040138238-A1 Substituted aminopyrimidine compounds as neurokinin antagonists TACR1, GRPR, BDKRB1 MAPT 1853/4885SMN1; SMN2 1992/4885HTT 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.